The European Venture Report covers dealmaking, exits and fundraising trends shaping the VC landscape across the continent. This edition spotlights the pharma & biotech sector and touches on trends such as extensive CVC participation in European deals and the dominant role software plays in the VC ecosystem. Figures of note from the 2Q edition include:
This report was updated on November 20, 2019 to correct an error in the "Capital invested (€B) from VC funds versus capital raised (€B)" for VC funds chart.
- €8.1 billion was invested across nearly 1,100 deals this quarter, marking Europe's highest quarterly deal value on record
- After unprecedented IPO activity in 2018, only 14 public listings worth €840.0 million closed in 1H 2019
- €5.3 billion poured into 40 funds in 1H, signaling a stabilization within the fundraising environment